Launch

iMDx launches second stock offering of 2026 to fund transplant test push

What's the deal? Insight Molecular Diagnostics (Nasdaq: IMDX), formerly OncocyteDealroom has a profile for this one. Try Dealroom →, has launched an underwritten public offering of common stock, with pre-funded warrants available to certain investors in place of shares. Lake Street Capital MarketsDealroom has a profile for this one. Try Dealroom → is acting as sole managing underwriter.

The terms: The Nashville-based company plans to grant the underwriter a 30-day option to buy up to an additional 15% of the total shares offered. It has not yet disclosed the size or terms, and said completion is not assured.

Why now? The raise comes as iMDx advances GraftAssureDx, its kidney-transplant rejection test, which it submitted to the US Food and Drug Administration (FDA) in March and is preparing to commercialize. Proceeds are earmarked for working capital and general corporate purposes, including research and development in transplantation.

This is the company's second notable equity raise this year. In February, it completed a $26 million registered direct offering, netting about $24.6 million, with proceeds partly aimed at transplant-testing R&D.

What could go wrong? The back-to-back offerings underscore iMDx's ongoing dependence on equity funding and add potential dilution for existing shareholders. It also faces established dd-cfDNA testing rivals CareDx and Natera.

The signal: The financing supports a key regulatory and launch transition, bridging iMDx from FDA submission to commercialization in a crowded transplant-diagnostics market.

Read more: streetinsider.com

Image credit: "USAMRUK Malaria Diagnostics and Control Center of Excellence microscopy training - Nigeria, Africa, September 2009" by US Army Africa, licensed under CC BY 2.0

More top stories